公开(公告)号：US09023609B2

公开(公告)日：2015-05-05

申请号：US13809697

申请日：2011-07-11

Applicant: Aida Inbal ,  Esther Rabizadeh

Inventor： Aida Inbal ,  Esther Rabizadeh

IPC: C12Q1/37 ,  G01N33/574

CPC classification number: C12Q1/37 ,  G01N33/574

Abstract: The present invention reveals a strong correlation between FGL-2 prothrombinase activity levels and the presence of a malignant proliferative disorder in a subject. Thus, the present invention provides FGL-2 prothrombinase activity as a diagnostic tool for malignancy.

Abstract translation: 本发明揭示了FGL-2凝血酶原酶活性水平与受试者中恶性增殖性病症的存在之间的强相关性。 因此，本发明提供FGL-2凝血酶原酶活性作为恶性肿瘤的诊断工具。

公开(公告)号：US20130115645A1

公开(公告)日：2013-05-09

申请号：US13809697

申请日：2011-07-11

Applicant: Aida Inbal ,  Esther Rabizadeh

Inventor： Aida Inbal ,  Esther Rabizadeh

IPC: C12Q1/37

CPC classification number: C12Q1/37 ,  G01N33/574

Abstract: The present: invention reveals a strong correlation between FGL-2 prothrombinase activity levels and the presence of a malignant proliferative disorder in a subject. Thus, the present invention provides FGL-2 prothrombinase activity as a diagnostic tool for malignancy.

Abstract translation: 本发明揭示了FGL-2凝血酶原酶活性水平与受试者中恶性增殖性病症的存在之间的强相关性。 因此，本发明提供FGL-2凝血酶原酶活性作为恶性肿瘤的诊断工具。

公开(公告)号：US06489290B2

公开(公告)日：2002-12-03

申请号：US09381261

申请日：1999-12-07

Applicant: Joseph Loscalzo ,  Aida Inbal

Inventor： Joseph Loscalzo ,  Aida Inbal

IPC: A61K3800

CPC classification number: C07K14/355 ,  A61K38/00

Abstract: This invention combines the unique antiplatelet effects of S-nitrosothiols and the antiadhesive properties of fragments of von Willebrand (vWF) in the A1 domain to provide unique molecules that exploit both of these properties. Preferred molecules comprise a fragment of A1 (Ala 444-Asn 730) in which arginine at position 545 is replaced by cysteine (the most frequent von Willebrand disease type 2b mutation) that has been discovered to impair platelet adhesion, and to inhibit an antithrombotic activity in vivo. This cysteine residue may be S-nitrosated to produce a novel molecule that has the potential for impairing platelet adhesion as well as activation/aggregation, and such molecules form the basis of a novel therapeutic method for impairing platelet responses following vascular injury or in other thrombotic disorders according to this invention.

Abstract translation: 本发明结合了S-亚硝基硫醇的独特的抗血小板作用和缬沙坦（vWF）片段在A1结构域中的抗粘附性，以提供独特的分子，利用这两种特性。 优选的分子包含A1（Ala 444-Asn 730）的片段，其中545位的精氨酸被已被发现损伤血小板粘附的半胱氨酸（最常见的血管性血友病血型B型突变）代替，并且抑制抗血栓形成活性 体内。 该半胱氨酸残基可以被S-亚硝基化以产生具有损害血小板粘附和活化/聚集的潜力的新分子，并且这些分子形成用于损伤血管损伤或其它血栓形成后血小板反应的新型治疗方法的基础 根据本发明的病症。

公开(公告)号：US20070167361A1

公开(公告)日：2007-07-19

申请号：US10589957

申请日：2005-02-15

Applicant: Aida Inbal ,  Rima Dardik ,  Jonathan Leor ,  Gerhard Dickneite

Inventor： Aida Inbal ,  Rima Dardik ,  Jonathan Leor ,  Gerhard Dickneite

IPC: A61K38/37

CPC classification number: A61K38/45

Abstract: Subject of the present invention is the use of a Factor XIII-preparation preferably in injectable form for the treatment of diseases which are associated with disturbed blood perfusion of the tissue following transient or permanent ischemia.

Abstract translation: 本发明的主题是优选以可注射形式的因子XIII-制剂用于治疗与暂时性或永久性局部缺血后组织受干扰的血液灌注相关的疾病的用途。